Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 4.86
GIFLF's Cash to Debt is ranked higher than
65% of the 1239 Companies
in the Global Biotechnology industry.

( Industry Median: 60.65 vs. GIFLF: 4.86 )
GIFLF' s 10-Year Cash to Debt Range
Min: 0.07   Max: No Debt
Current: 4.86

Equity to Asset 0.31
GIFLF's Equity to Asset is ranked higher than
55% of the 922 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. GIFLF: 0.31 )
GIFLF' s 10-Year Equity to Asset Range
Min: 0.28   Max: 0.37
Current: 0.31

0.28
0.37
Interest Coverage 3.07
GIFLF's Interest Coverage is ranked lower than
52% of the 574 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. GIFLF: 3.07 )
GIFLF' s 10-Year Interest Coverage Range
Min: 1.56   Max: 18.28
Current: 3.07

1.56
18.28
F-Score: 7
Z-Score: 2.34
M-Score: -2.23
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 9/10

vs
industry
vs
history
Operating margin (%) 25.56
GIFLF's Operating margin (%) is ranked higher than
94% of the 1013 Companies
in the Global Biotechnology industry.

( Industry Median: -78.59 vs. GIFLF: 25.56 )
GIFLF' s 10-Year Operating margin (%) Range
Min: 15.53   Max: 26.85
Current: 25.56

15.53
26.85
Net-margin (%) 13.32
GIFLF's Net-margin (%) is ranked higher than
90% of the 1013 Companies
in the Global Biotechnology industry.

( Industry Median: -70.38 vs. GIFLF: 13.32 )
GIFLF' s 10-Year Net-margin (%) Range
Min: 2.8   Max: 16.2
Current: 13.32

2.8
16.2
ROE (%) 18.89
GIFLF's ROE (%) is ranked higher than
95% of the 1134 Companies
in the Global Biotechnology industry.

( Industry Median: -34.93 vs. GIFLF: 18.89 )
GIFLF' s 10-Year ROE (%) Range
Min: 4.27   Max: 18.34
Current: 18.89

4.27
18.34
ROA (%) 6.12
GIFLF's ROA (%) is ranked higher than
91% of the 1239 Companies
in the Global Biotechnology industry.

( Industry Median: -28.51 vs. GIFLF: 6.12 )
GIFLF' s 10-Year ROA (%) Range
Min: 1.34   Max: 6.51
Current: 6.12

1.34
6.51
ROC (Joel Greenblatt) (%) 40.99
GIFLF's ROC (Joel Greenblatt) (%) is ranked higher than
94% of the 1212 Companies
in the Global Biotechnology industry.

( Industry Median: -442.83 vs. GIFLF: 40.99 )
GIFLF' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 19.07   Max: 42.94
Current: 40.99

19.07
42.94
» GIFLF's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Insider Trades

Latest Guru Trades with GIFLF

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Guru Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 29.60
GIFLF's P/E(ttm) is ranked higher than
94% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. GIFLF: 29.60 )
GIFLF' s 10-Year P/E(ttm) Range
Min: 19.05   Max: 102.43
Current: 29.6

19.05
102.43
P/B 4.80
GIFLF's P/B is ranked higher than
76% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 5.76 vs. GIFLF: 4.80 )
GIFLF' s 10-Year P/B Range
Min: 2.33   Max: 6.76
Current: 4.8

2.33
6.76
P/S 3.90
GIFLF's P/S is ranked higher than
92% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 32.74 vs. GIFLF: 3.90 )
GIFLF' s 10-Year P/S Range
Min: 1.87   Max: 6.66
Current: 3.9

1.87
6.66
PFCF 19.80
GIFLF's PFCF is ranked higher than
97% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. GIFLF: 19.80 )
GIFLF' s 10-Year PFCF Range
Min: 16.28   Max: 1198.5
Current: 19.8

16.28
1198.5
EV-to-EBIT 14.40
GIFLF's EV-to-EBIT is ranked higher than
97% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. GIFLF: 14.40 )
GIFLF' s 10-Year EV-to-EBIT Range
Min: 11.7   Max: 47
Current: 14.4

11.7
47
PEG 1.04
GIFLF's PEG is ranked higher than
99% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. GIFLF: 1.04 )
GIFLF' s 10-Year PEG Range
Min: 0   Max: 2
Current: 1.04

0
2
Current Ratio 2.75
GIFLF's Current Ratio is ranked higher than
64% of the 1228 Companies
in the Global Biotechnology industry.

( Industry Median: 4.73 vs. GIFLF: 2.75 )
GIFLF' s 10-Year Current Ratio Range
Min: 2.19   Max: 3.26
Current: 2.75

2.19
3.26
Quick Ratio 1.59
GIFLF's Quick Ratio is ranked higher than
58% of the 1228 Companies
in the Global Biotechnology industry.

( Industry Median: 4.53 vs. GIFLF: 1.59 )
GIFLF' s 10-Year Quick Ratio Range
Min: 1.15   Max: 1.88
Current: 1.59

1.15
1.88

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 0.50
GIFLF's Dividend Yield is ranked lower than
68% of the 194 Companies
in the Global Biotechnology industry.

( Industry Median: 1.13 vs. GIFLF: 0.50 )
GIFLF' s 10-Year Dividend Yield Range
Min: 0.38   Max: 0.6
Current: 0.5

0.38
0.6
Dividend Payout 0.13
GIFLF's Dividend Payout is ranked higher than
99% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. GIFLF: 0.13 )
GIFLF' s 10-Year Dividend Payout Range
Min: 0.19   Max: 0.59
Current: 0.13

0.19
0.59
Yield on cost (5-Year) 0.50
GIFLF's Yield on cost (5-Year) is ranked lower than
65% of the 199 Companies
in the Global Biotechnology industry.

( Industry Median: 1.17 vs. GIFLF: 0.50 )
GIFLF' s 10-Year Yield on cost (5-Year) Range
Min: 0.38   Max: 0.6
Current: 0.5

0.38
0.6

Valuation & Return

vs
industry
vs
history
Price/Median PS Value 1.00
GIFLF's Price/Median PS Value is ranked higher than
84% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 2.90 vs. GIFLF: 1.00 )
GIFLF' s 10-Year Price/Median PS Value Range
Min: 0.56   Max: 1.59
Current: 1

0.56
1.59
Earnings Yield (Greenblatt) 6.90
GIFLF's Earnings Yield (Greenblatt) is ranked higher than
96% of the 1174 Companies
in the Global Biotechnology industry.

( Industry Median: -6.40 vs. GIFLF: 6.90 )
GIFLF' s 10-Year Earnings Yield (Greenblatt) Range
Min: 2.1   Max: 8.6
Current: 6.9

2.1
8.6

Business Description

Industry: Biotechnology » Biotechnology
Compare: » details
Traded in other countries:GRFS.USA, GRF.P.Spain, 0EM7.UK, GRF.Spain, G0FB.Germany, OZT.Germany
Grifols SA Was incorporated on June 22, 1987. It is a specialty biopharmaceutical company that develops, manufactures and distributes a broad range of plasma derivative products. Its products and services are used by healthcare providers to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases and a range of other medical conditions. The Company operates in four business divisions: Bioscience, Diagnostic, Hospital and Raw Materials and Others. The Bioscience division includes activities relating to the manufacture of plasma derivatives for therapeutic use, including the reception, analysis, quarantine, classification, fractionation and purification of plasma, and the sale and distribution of end products. The main plasma products it manufactures are IVIG, Factor VIII, A1PI and albumin. It also manufactures intramuscular immunoglobulins, ATIII, Factor IX and plasma thromboplastin component, or PTC. The Diagnostic division focuses on researching, developing, manufacturing and marketing in vitro diagnostics products, including analytical instruments and reagents for diagnostics, as well as blood bank products. The Company concentrates its Diagnostic business in immunohematology and hemostasis product lines. The Diagnostic division's main customers are blood donation centers, clinical analysis laboratories and hospital immunohematology services. The Raw Material division provides raw materials for its intravenous therapy products like plastic and glass bottles, which the company purchases from various European suppliers. The Hospital division manufactures and installs products used by and in hospitals, such as parenteral solutions and enteral and parenteral nutritional fluids, which are sold almost exclusively in Spain and Portugal. It also includes products that the company do not manufacture. The Company operates in Latin America, in countries such as Mexico, Colombia, Argentina, Chile and Brazil. It sells Bioscience, Diagnostic and Hospital products to hospitals and clinics, GPOs, governments and other distributors globally. The Company's operations are subject to government authorities in the United States, at the federal, state and local level, and in other countries in which it operates.
» More Articles for GIFLF

Headlines

Articles On GuruFocus.com
Gold-Focused Guru John Paulson Reports First Quarter Holdings May 22 2014 
Is Grifols Being Overlooked? Mar 19 2014 
John Paulson's Top Five Holdings Nov 20 2013 
John Paulson's Top Five Holdings Sep 12 2013 
Baron Funds Comments on Grifols SA Aug 30 2012 
Friday Value Overview Aug 19 2011 

More From Other Websites
No related articles found.

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK